---
title: Aplastic Anemia (INICET Cheat Sheet)
markmap:
  colorFreezeLevel: 6
---

## Aplastic Anemia
- **Definition**: Pancytopenia with Hypocellular Bone Marrow
- **Etiology** <!-- markmap: fold -->
  - **Idiopathic** (Most Common, Immune-mediated)
  - **Secondary**
    - Drugs: Chloramphenicol, Sulfonamides, NSAIDs (Phenylbutazone), Gold Salts, Anticonvulsants (Phenytoin), Chemo
    - Toxins: Benzene, Pesticides, Radiation
    - Viruses: Hepatitis (Non A-E most common post-hepatitic AA), EBV, HIV, Parvovirus B19 (Transient Aplastic Crisis)
    - Immunologic: PNH (often coexist or evolve)
    - Inherited Syndromes: Fanconi Anemia (Most common inherited AA), Dyskeratosis Congenita, Shwachman-Diamond, Severe Congenital Neutropenia
- **Pathophysiology** <!-- markmap: fold -->
  - **Immune-mediated**: T-cell destruction of Hematopoietic Stem Cells (HSCs)
  - Defective HSCs
- **Clinical Features** <!-- markmap: fold -->
  - Symptoms of Pancytopenia
    - Anemia: Fatigue, Pallor, Dyspnea
    - Thrombocytopenia: Bleeding (Petechiae, Purpura, Mucosal)
    - Neutropenia: Infections (Bacterial, Fungal), Fever
- **Diagnosis** <!-- markmap: fold -->
  - **CBC**: Pancytopenia (Hb, Platelets, ANC Low)
  - **Peripheral Smear**: Normocytic/Macrocytic RBCs, low Reticulocytes
  - **Bone Marrow Biopsy**: **Key Diagnostic Test**
    - **Hypocellularity** (<25% cellularity or <50% with marked fat increase & <30% residual cells)
    - **Increased Fat Spaces**
    - **Absence of significant blasts** (<5%)
    - **Absence of significant dysplasia**
    - Rule out other causes (MDS, PNH, Leukemia, B12/Folate deficiency)
- **Severity Classification** (Based on Untreated Counts) <!-- markmap: fold -->
  - **Severe Aplastic Anemia (SAA)**: At least 2 of 3 AND BM Cellularity < 25% (or < 50% with < 30% HSC):
    - ANC < 500/µL
    - Platelets < 20,000/µL
    - Reticulocytes < 20,000/µL (<1%)
  - **Very Severe Aplastic Anemia (VSAA)**: SAA criteria PLUS ANC < 200/µL
  - **Non-Severe Aplastic Anemia (NSAA)**: Does not meet SAA criteria
- **Complications** <!-- markmap: fold -->
  - Infections (Leading cause of death)
  - Bleeding
  - **PNH** (Clonal evolution)
  - **MDS/AML** (Transformation risk, especially with IST)
- **Management** <!-- markmap: fold -->
  - **Supportive Care**:
    - Blood Transfusions (Minimize alloimmunization, filter)
    - Platelet Transfusions (Thresholds for active bleeding/procedures)
    - G-CSF (For severe infections, not routine)
    - Infection Prophylaxis/Treatment
  - **Specific Treatment (for SAA/VSAA)**:
    - **Hematopoietic Stem Cell Transplant (HSCT)**:
      - **Treatment of Choice** for young patients (<40-50) with Matched Sibling Donor (MSD)
      - Higher success, lower relapse/clonal evolution than IST
    - **Immunosuppressive Therapy (IST)**:
      - For patients without MSD, older patients
      - **Standard**: **ATG (Anti-thymocyte globulin) + Cyclosporine**
      - **Eltrombopag**: Thrombopoietin receptor agonist, improves counts across all lineages, used with IST or refractory AA.
    - **NSAA**: Observation or Cyclosporine if symptomatic
- **Prognosis**: Varies with severity & treatment. Better with HSCT in young patients.
- **INICET Buzzwords** <!-- markmap: fold -->
  - Pancytopenia
  - Hypocellular Bone Marrow
  - Idiopathic Aplastic Anemia
  - Chloramphenicol
  - Benzene
  - Post-hepatitic AA
  - Parvovirus B19 (Transient Aplastic Crisis)
  - Fanconi Anemia
  - Dyskeratosis Congenita
  - T-cell mediated
  - ATG + Cyclosporine
  - HSCT (Matched Sibling Donor)
  - SAA / VSAA
  - Eltrombopag
  - PNH (Clonal Evolution)
  - Increased Fat (BM)
